Single nucleotide polymorphism leads to daptomycin resistance causing amino acid substitution-T345I in MprF of clinically isolated MRSA strains.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2021
Historique:
received: 30 03 2020
accepted: 06 01 2021
entrez: 22 1 2021
pubmed: 23 1 2021
medline: 22 6 2021
Statut: epublish

Résumé

Daptomycin (DAP) is one of the most potent antibiotics used for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. Due to an increase in its administration for combating MRSA infections, DAP non-susceptible (DAP-NS) MRSA strains have recently been reported in clinical settings. The presence of single nucleotide polymorphisms (SNPs) in the multiple peptide resistance factor (mprF) gene is the most frequently reported cause for the evolution of DAP-NS MRSA strains; however, there are some variations of SNPs that could lead to DAP-NS. In this study, we used two clinical MRSA strains, including DAP susceptible (DAP-S) and DAP-NS, isolated from the same patient at different time points. We introduced T345I SNP to mprF of the DAP-S MRSA strain using the gene exchange method with pIMAY vector. Further, we investigated the phenotype of the mutant strain, including drug susceptibility, cell surface positive charge, and growth speed. The mutant strain exhibited (i) resistance to DAP, (ii) up-regulation of positive surface charge, (iii) slower growth speed, and (iv) thickened cell walls. Hence, the SNP in mprF may have caused an up-regulation in MprF function, with a subsequent increase in positive surface charge. Cumulatively, these results demonstrated that the T345I amino acid substitution in mprF represents one of the primary causes of DAP-NS in MRSA strains.

Identifiants

pubmed: 33481910
doi: 10.1371/journal.pone.0245732
pii: PONE-D-20-09016
pmc: PMC7822245
doi:

Substances chimiques

Bacterial Proteins 0
Aminoacyltransferases EC 2.3.2.-
mprF protein, Staphylococcus aureus EC 2.3.2.-
Daptomycin NWQ5N31VKK

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0245732

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Can J Infect Dis Med Microbiol. 2012 Summer;23(2):e48-50
pubmed: 23730321
Int J Infect Dis. 2002 Dec;6(4):302-8
pubmed: 12718825
Antimicrob Agents Chemother. 2007 Sep;51(9):3445-8
pubmed: 17620372
Antimicrob Agents Chemother. 2014 Dec;58(12):7462-7
pubmed: 25288091
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30858203
J Clin Microbiol. 2008 Mar;46(3):1132-6
pubmed: 18199793
Antimicrob Agents Chemother. 1987 Jul;31(7):1014-6
pubmed: 2821883
PLoS One. 2012;7(1):e28316
pubmed: 22238576
Mol Microbiol. 2011 Apr;80(2):290-9
pubmed: 21306448
Front Microbiol. 2017 Nov 09;8:2199
pubmed: 29170657
Antimicrob Agents Chemother. 2009 Jun;53(6):2312-8
pubmed: 19332678
Antimicrob Agents Chemother. 2010 Dec;54(12):5222-33
pubmed: 20837752
PLoS One. 2018 Jun 7;13(6):e0198366
pubmed: 29879195
Antimicrob Agents Chemother. 2006 Jun;50(6):2137-45
pubmed: 16723576
BMC Infect Dis. 2014 Aug 23;14:459
pubmed: 25149872
PLoS Pathog. 2011 Nov;7(11):e1002359
pubmed: 22102812
J Appl Microbiol. 2006 Oct;101(4):938-47
pubmed: 16968305
Antimicrob Agents Chemother. 2011 Aug;55(8):3922-8
pubmed: 21606222
PLoS Pathog. 2009 Nov;5(11):e1000660
pubmed: 19915718
Antimicrob Agents Chemother. 2000 Sep;44(9):2276-85
pubmed: 10952568
J Med Microbiol. 2008 Aug;57(Pt 8):1036-1038
pubmed: 18628509
Antimicrob Agents Chemother. 2011 Sep;55(9):4012-8
pubmed: 21709105
mBio. 2012 Mar 20;3(2):
pubmed: 22434850
Infect Dis (Lond). 2017 May;49(5):410-416
pubmed: 28116950
J Infect Chemother. 2014 Sep;20(9):527-34
pubmed: 25066429
Scand J Infect Dis. 2010 Dec;42(11-12):955-7
pubmed: 20942775
Front Microbiol. 2018 May 25;9:1086
pubmed: 29887848
Microbiology (Reading). 2011 Jun;157(Pt 6):1786-1797
pubmed: 21393369
J Antimicrob Chemother. 1998 Aug;42(2):199-209
pubmed: 9738837

Auteurs

Masaki Nakamura (M)

Department of Microbiology, Kitasato University School of Allied Health Sciences, Kanagawa, Japan.
Department of Environmental Microbiology, Kitasato University Graduate School of Medical Sciences, Kanagawa, Japan.
Research Center for Infection control, Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan.

Hayato Kawada (H)

Department of Environmental Microbiology, Kitasato University Graduate School of Medical Sciences, Kanagawa, Japan.

Hiroki Uchida (H)

Department of Microbiology, Kitasato University School of Allied Health Sciences, Kanagawa, Japan.

Yusuke Takagi (Y)

Department of Microbiology, Kitasato University School of Allied Health Sciences, Kanagawa, Japan.

Shuichi Obata (S)

Department of Anatomical Sciences, Kitasato University School of Allied Health Sciences, Kanagawa, Japan.
Department of Histology and Cell Biology, Yokohama City University School of Medicine, Kanagawa, Japan.

Ryotaro Eda (R)

Department of Environmental Microbiology, Kitasato University Graduate School of Medical Sciences, Kanagawa, Japan.

Hideaki Hanaki (H)

Research Center for Infection control, Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan.

Hidero Kitasato (H)

Department of Microbiology, Kitasato University School of Allied Health Sciences, Kanagawa, Japan.
Department of Environmental Microbiology, Kitasato University Graduate School of Medical Sciences, Kanagawa, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH